Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.
Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
Type:
Application
Filed:
September 29, 2009
Publication date:
July 29, 2010
Applicant:
Cell Therapeutics, Inc.
Inventors:
Lynn BONHAM, J. Peter Klein, Robert E. Finney, David M. Hollenback, Scott A. Shaffer, Norina M. Tang, Thayer H. White, David W. Leung, Baoqing Gong, John Tulinsky
Abstract: The invention relates to a method for determining the amount of conjugated taxane, in particular paclitaxel, in a PGA-taxane conjugate said method comprising: a) reacting the PGA-taxane conjugate with a compound formula (I): R1R2N—NH2 (I), wherein R1 and R2 are as defined in the description; to give a unbound taxane and a PGA hydrazide and b) determining the amount of unbound taxane.
Type:
Application
Filed:
March 5, 2009
Publication date:
June 17, 2010
Applicant:
CELL THERAPEUTICS, INC.
Inventors:
Stefano Fazioni, Keith Hovda, Valeria Livi, Marc McKennon, Luigi Siviero, Holly Spoonemore
Abstract: This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.
Abstract: This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.
Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
Type:
Application
Filed:
October 14, 2008
Publication date:
December 3, 2009
Applicant:
Cell Therapeutics, Inc.
Inventors:
Marc Besman, Stewart Chipman, David Leung, Jack Singer
Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.
Type:
Grant
Filed:
August 6, 2007
Date of Patent:
November 17, 2009
Assignee:
Cell Therapeutics, Inc.
Inventors:
Rama Bhatt, Baoqing Gong, Feng Hong, Scott A Jenkins, J Peter Klein, Anil M Kumar, John Tulinsky
Abstract: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.
Type:
Application
Filed:
July 16, 2009
Publication date:
November 5, 2009
Applicant:
Stem Cell Therapeutics Inc
Inventors:
Bradley G. Thompson, Samuel Weiss, Tetsuro Shingo
Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
Type:
Grant
Filed:
November 16, 2006
Date of Patent:
October 27, 2009
Assignee:
Cell Therapeutics, Inc.
Inventors:
Lynn Bonham, Baoqing Gong, Robert E Finney, David M Hollenback, J Peter Klein, David W Leung, Scott A Shaffer, Norina M Tang, John Tulinsky, Thayer H White
Abstract: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.
Type:
Grant
Filed:
January 30, 2006
Date of Patent:
October 20, 2009
Assignee:
Stem Cell Therapeutics Inc.
Inventors:
Bradley G. Thompson, Samuel Weiss, Tetsuro Shingo
Abstract: The use of an arylidene 2-indolinone derivative for treating tumors involving Met, PDGF-R, FGF-RI, FGF-R3 or Kit tyrosine kinases, or a Ret oncoprotein which includes a MEN2-associated mutation is disclosed.
Type:
Application
Filed:
November 13, 2008
Publication date:
May 21, 2009
Applicants:
Cell Therapeutics, Inc., Instituto Nazionale per lo Studio e la Cura dei Tumori
Inventors:
Cinzia Lanzi, Giuliana Cassinelli, Giuditta Cuccuru, Marco A. Pierotti, Franco Zunino, Ernesto Menta
Abstract: The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor-cells.
Type:
Application
Filed:
August 19, 2008
Publication date:
April 16, 2009
Applicant:
Cell Therapeutics, Inc.
Inventors:
Rama BHATT, Baoqing GONG, Feng HONG, Scott A. JENKINS, J. Peter KLEIN, Cory T. KOHM, John TULINSKY
Abstract: The invention relates to the use of compounds of general formula (I), in which R1, R2 and X are as defined in the description for the preparation of pharmaceutical compositions for the treatment of pathologies in which inhibition of the interaction between HIF-1? and p300 is beneficial, in particular as antiangiogenic medicaments for the therapy of solid tumors.
Type:
Application
Filed:
December 19, 2005
Publication date:
October 23, 2008
Applicant:
Cell Therapeutics, Inc.
Inventors:
Mara Cassin, Gennaro Colella, Sergio De Munari, Mario Grugni
Abstract: The invention relates to the use of diketodithiopiperazine antibiotics, in particular chaetocin and gliotoxin, for the preparation of pharmaceutical compositions for antitumor therapy.
Type:
Application
Filed:
December 14, 2005
Publication date:
October 16, 2008
Applicant:
Cell Therapeutics, Inc.
Inventors:
Sergio De Munari, Mario Grugni, Ernesto Menta, Mara Cassin, Gennaro Colella
Abstract: The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor-cells.
Type:
Grant
Filed:
September 24, 2003
Date of Patent:
September 2, 2008
Assignee:
Cell Therapeutics, Inc.
Inventors:
Rama Bhatt, Baoqing Gong, Feng Hong, Scott A Jenkins, J Peter Klein, Cory T Kohm, John Tulinsky
Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.
Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.
Type:
Grant
Filed:
April 2, 2003
Date of Patent:
July 15, 2008
Assignee:
Cell Therapeutics Inc.
Inventors:
Anil M. Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.
Abstract: The present invention discloses combinations of drug conjugates with other therapeutic agents, including chemotherapy drugs. The invention also provides methods of using the combinations for the treatment of diseases associated with cell proliferation, such as tumors.
Abstract: The present invention relates to a method of increasing the number and/or differentiation of neural stem cells and/or neural stem cell progeny using pituitary adenylate cyclase-activating polypetide (PACAP). In a preferred embodiment, additional growth factors are also utilized. The present invention can be practiced in vivo and in vitro, rendering it useful for the treatment of neurodegenerative disease and other neural trauma.